Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China

Abstract Background Dasatinib and imatinib are the recommended tyrosine kinase inhibitors (TKIs) for treating pediatric Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL), and the one which has been approved indication in China is imatinib. Recently, clinical demand for Ph + ALL treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Wang Cao (Author), Yuncui Yu (Author), Yingpeng Qiu (Author), Lu Liu (Author), Hao Zhang (Author), Liwei Shi (Author), Yue Xiao (Author), Lulu Jia (Author), Ruidong Zhang (Author), Xiaoling Wang (Author)
Format: Book
Published: BMC, 2022-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available